A Phase I, Open-label, Single-dose Trial to Investigate Metabolism and Pharmacokinetics of [14C]BI 1482694 Administered as Oral Solution in Healthy Male Volunteers
Phase of Trial: Phase I
Latest Information Update: 15 Jul 2016
At a glance
- Drugs Olmutinib (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 27 Jun 2016 Status changed from active, no longer recruiting to completed.
- 16 May 2016 Status changed from recruiting to active, no longer recruiting.
- 03 May 2016 Status changed from not yet recruiting to recruiting.